Document is current
Any future updates will be listed below
-
Authors
Ruicci, Kara M.
Deng, Yangqing
Xiao, Tian
Eskander, Antoine
Goldstein, David
Mete, Ozgur
Mesci, Aruz
Lukovic, Jelena
Krzyzanowska, Monika K.
Barron, Carly C.
Ma, Lucy X. https://orcid.org/0000-0003-1407-0715
- License Information
-
More Information
Article History
Received: 29 January 2025
Revised: 21 April 2025
Accepted: 9 May 2025
First Online: 3 June 2025
Competing interests
: LXM is a consultant for Eisai and Bristol Myers Squibb. OM has served as an advisory board member for Bayer regarding the multidisciplinary Canadian consensus on the multimodal management of high-risk and radioactive iodine-refractory thyroid carcinoma, and also for Eli Lilly Canada (facilitated directly via Precision RxDx) for participation in working group meetings on Recommendations on Actionable Biomarker Testing for Thyroid Cancer Management. MKK reports funding from Eisai, Exelixis, Ipsen, Eli Lilly and Novartis, and is on the Data Safety Monitoring Board for Novartis, and is an advisory board member for Ipsen. All other authors have declared no competing interests.
: This study was approved by the University Health Network (UHN) Research Ethics Board (CAPCR 23-5561). The study was performed in accordance with the Declaration of Helsinki.
